The hypothesis that HO-1 could be a potential therapeutic target for DMD, is supported by studies, where sulforaphane treatment of mdx mice activated in skeletal muscles the HO-1 expression in Nrf2 dependent way, what resulted in reduction of infiltration of immune cells and expression of the inflammatory cytokines (TNF-α, IL-1β and IL-6) (Sun et al. 2015). Here, HMOX1 is linked to Duchenne muscular dystrophy.